

Advancing IgAN Care: Expert Strategies for Transformative Patient Outcomes – Additional Resources

IgA nephropathy

Stamellou E, Seikrit C, Tang SCW, Boor P, Tesaf V, Floege J, Barratt J, Kramann R. IgA nephropathy. *Nat Rev Dis Primers*. 2023 Nov 30;9(1):67. doi: 10.1038/s41572-023-00476-9. PMID: 38036542.

Link: <https://pubmed.ncbi.nlm.nih.gov/38036542/>

A Phase 2 Trial of Sibeprenlimab in Patients with IgA Nephropathy

Mathur M, Barratt J, Chacko B, Chan TM, Kooienga L, Oh KH, Sahay M, Suzuki Y, Wong MG, Yarbrough J, Xia J, Pereira BJB; ENVISION Trial Investigators Group. A Phase 2 Trial of Sibeprenlimab in Patients with IgA Nephropathy. *N Engl J Med*. 2024 Jan 4;390(1):20-31. doi: 10.1056/NEJMoa2305635. Epub 2023 Nov 2. PMID: 37916620; PMCID: PMC7615905.

Link: <https://pubmed.ncbi.nlm.nih.gov/37916620/>

Results of a randomized double-blind placebo-controlled Phase 2 study propose iptacopan as an alternative complement pathway inhibitor for IgA nephropathy

Zhang H, Rizk DV, Perkovic V, Maes B, Kashihara N, Rovin B, Trimarchi H, Sprangers B, Meier M, Kollins D, Papachristofi O, Milojevic J, Junge G, Nidamarthy PK, Charney A, Barratt J. Results of a randomized double-blind placebo-controlled Phase 2 study propose iptacopan as an alternative complement pathway inhibitor for IgA nephropathy. *Kidney Int*. 2024 Jan;105(1):189-199. doi: 10.1016/j.kint.2023.09.027. Epub 2023 Oct 31. PMID: 37914086.

Link: <https://pubmed.ncbi.nlm.nih.gov/37914086/>

Sparsentan in patients with IgA nephropathy: a prespecified interim analysis from a randomised, double-blind, active-controlled clinical trial

Heerspink HJL, Radhakrishnan J, et al. PROTECT Investigators. Sparsentan in patients with IgA nephropathy: a prespecified interim analysis from a randomised, double-blind, active-controlled clinical trial. *Lancet*. 2023 May 13;401(10388):1584-1594. doi: 10.1016/S0140-6736(23)00569-X. Epub 2023 Apr 1. PMID: 37015244.

Link: [https://www.thelancet.com/journals/lancet/article/PIIS0140-6736\(23\)00569-X/fulltext](https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(23)00569-X/fulltext)

KDIGO 2021 Clinical Practice Guideline for the Management of Glomerular Diseases

Kidney Disease: Improving Global Outcomes (KDIGO) Glomerular Diseases Work Group. KDIGO 2021 Clinical Practice Guideline for the Management of Glomerular Diseases. *Kidney Int.* 2021 Oct;100(4S):S1-S276. doi: 10.1016/j.kint.2021.05.021. PMID: 34556256.

Link: [https://www.kidney-international.org/article/S0085-2538\(21\)00562-7/fulltext](https://www.kidney-international.org/article/S0085-2538(21)00562-7/fulltext)

Sparsentan: First Approval

Syed YY. Sparsentan: First Approval. *Drugs.* 2023 Apr;83(6):563-568. doi: 10.1007/s40265-023-01864-x. PMID: 37022667.

Link: <https://link.springer.com/article/10.1007/s40265-023-01864-x>

Long-term outcomes in IgA nephropathy

Pitcher D, Braddon F, Hendry B, Mercer A, Osmaston K, Saleem MA, Steenkamp R, Wong K, Turner AN, Wang K, Gale DP, Barratt J. Long-Term Outcomes in IgA Nephropathy. *Clin J Am Soc Nephrol.* 2023 Jun 1;18(6):727-738. doi: 10.2215/CJN.000000000000135. Epub 2023 Apr 13. PMID: 37055195.

Link: https://journals.lww.com/cjasn/Fulltext/2023/06000/Long_Term_Outcomes_in_IgA_Nephropathy.9.aspx

Targeting the Endothelin A Receptor in IgA Nephropathy

Kohan DE, Barratt J, Heerspink HJL, Campbell KN, Camargo M, Ogbaa I, Haile-Meskale R, Rizk DV, King A. Targeting the Endothelin A Receptor in IgA Nephropathy. *Kidney Int Rep.* 2023 Aug 4;8(11):2198-2210. doi: 10.1016/j.ekir.2023.07.023. PMID: 38025243; PMCID: PMC10658204.

Link: <https://pubmed.ncbi.nlm.nih.gov/38025243/>

Efficacy and safety of a targeted-release formulation of budesonide in patients with primary IgA nephropathy (NeflgArd): 2-year results from a randomised phase 3 trial

Lafayette R, Kristensen J, Stone A, Floege J, Tesar V, Trimarchi H, Zhang H, Eren N, Paliege A, Reich HN, Rovin BH, Barratt J; NeflgArd trial investigators. Efficacy and safety of a targeted-release formulation of budesonide in patients with primary IgA nephropathy (NeflgArd): 2-year results from a randomised phase 3 trial. *Lancet.* 2023 Sep 9;402(10405):859-870. doi: 10.1016/S0140-6736(23)01554-4. Epub 2023 Aug 14. Erratum in: *Lancet.* 2023 Sep 9;402(10405):850. PMID: 37591292.

<https://pubmed.ncbi.nlm.nih.gov/37591292/>